These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 31521831)

  • 1. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
    Busse WW; Maspero JF; Lu Y; Corren J; Hanania NA; Chipps BE; Katelaris CH; FitzGerald JM; Quirce S; Ford LB; Rice MS; Kamat S; Khan AH; Jagerschmidt A; Harel S; Rowe P; Pirozzi G; Amin N; Ruddy M; Graham NMH; Teper A
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):565-576.e1. PubMed ID: 32474156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
    Tohda Y; Nakamura Y; Fujisawa T; Ebisawa M; Arima K; Miyata M; Takahashi Y; Rice MS; Deniz Y; Rowe P; Patel N; Graham NMH; Teper A
    Allergol Int; 2020 Oct; 69(4):578-587. PubMed ID: 32444306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
    Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
    Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
    Rabe KF; FitzGerald JM; Bateman ED; Castro M; Pavord ID; Maspero JF; Busse WW; Izuhara K; Daizadeh N; Ortiz B; Pandit-Abid N; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2916-2924.e4. PubMed ID: 36028446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
    Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
    Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
    Corren J; Katelaris CH; Castro M; Maspero JF; Ford LB; Halpin DMG; Rice MS; Radwan A; Deniz Y; Rowe PJ; Teper A; Djandji M
    Eur Respir J; 2021 Oct; 58(4):. PubMed ID: 34266940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
    Corren J; Hanania NA; Busse WW; Sher LD; Altincatal A; Hardin M; Mannent LP; Amin N; Lederer DJ; Soler X; Jacob-Nara JA; Rowe PJ; Deniz Y
    Clin Exp Allergy; 2023 Oct; 53(10):1020-1030. PubMed ID: 37752621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
    Rabe KF; Pavord ID; Busse WW; Chupp GL; Izuhara K; Altincatal A; Gall R; Pandit-Abid N; Deniz Y; Rowe PJ; Jacob-Nara JA; Radwan A
    Allergy; 2023 Aug; 78(8):2148-2156. PubMed ID: 37073882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
    Papadopoulos NG; Szefler SJ; Bacharier LB; Maspero JF; Domingo C; Fiocchi A; Lee JK; Daizadeh N; Lederer DJ; Hardin M; Gall R; Djandji M; Siddiqui S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Allergy; 2023 Aug; 78(8):2157-2167. PubMed ID: 37059696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.
    Peters AT; Sagara H; Corren J; Domingo C; Altincatal A; Soler X; Pandit-Abid N; Crikelair N; Rowe PJ; Jacob-Nara JA; Deniz Y
    Ann Allergy Asthma Immunol; 2024 Apr; 132(4):477-484.e4. PubMed ID: 38013139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
    Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
    Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
    Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
    Sher LD; Corren J; Pavord ID; Daizadeh N; Altincatal A; Soler X; Djandji M; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    J Asthma; 2023 Sep; 60(9):1767-1774. PubMed ID: 36876957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
    Pavord ID; Casale TB; Corren J; FitzGerald MJ; Deniz Y; Altincatal A; Gall R; Pandit-Abid N; Radwan A; Jacob-Nara JA; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1763-1772. PubMed ID: 38555079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.